New Chairman of the Board at Aratana Therapeutics
The board of directors for Aratana Therapeutics Inc., a pet therapeutics manufacturer, has elected Wendy Yarno as the company’s chairman of the board.
"I am delighted to transition the chairmanship to Ms. Yarno,” said Jay Lichter, Ph.D., who resigned from the board to pursue a venture capital career and who Yarno is replacing.
“Given her extensive commercial expertise and experience at multiple multinational healthcare companies,” added Dr. Lichter, “we view this as a strategic move as we transition from a development-stage company to one that also has commercial operations.”
Aratana Therapeutics Inc. of Kansas City, Kan., focuses on the licensing, development and bringing to market biopharmaceutical products for pets.
"Aratana has had a great deal of recent success in its development pipeline. With this success, the company has moved closer to its objective of having six products on the market next year. I look forward to applying my expertise during this exciting time of growth for Aratana," Yarno said about her new role.
Yarno has been a member of Aratana’s board since 2013 and previously held several management positions and lead multiple business groups during her 26 years at Merck & Co. Inc., including chief marketing officer where she led a team of more than 3,000 responsible for supporting product commercialization across more than 20 therapeutic areas.
In addition to her board position with Aratana, Yarno also holds public company board positions with St. Jude Medical Inc. and Medivation Inc.